Illumina is emerging from a turbulent post-GRAIL period, with Q2 2026 revenue growth of 9.7% YoY and operating margin expansion to 21.1% from 17.7% a year earlier. The balance sheet has deleveraged significantly, with D/E down to 0.89 from 2.03 in Q2 2024, and...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth turned positive at 9.7% YoY in Q2 2026, with gross margin stable at 66.4% and operating margin expanding to 21.1%, though TTM revenue is still down 0.8%.
Illumina reported Q1 2026 revenue of $1,091 million and net income of $134 million, with higher EPS YoY and raised full-year revenue guidance to $4.52-$4.62 billion.
The company repurchased about 7.15% of its stock, demonstrating management's confidence in the business outlook.
Illumina offers a broad range of sequencing and microarray products for various genomic analysis applications, driving advances in research and diagnostics.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $1.31+6.5% vs $1.23 | $1.2B+2.5% vs $1.1B |
Q2 2026 Apr 30, 2026 | $1.15+9.5% vs $1.05 | $1.1B+1.7% vs $1.1B |
Q1 2026 Feb 5, 2026 | $1.35+8.9% vs $1.24 | $1.2B+3.6% vs $1.1B |
Q4 2025 Oct 30, 2025 | $1.34+14.5% vs $1.17 | $1.1B+1.6% vs $1.1B |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Baird Financial Group Inc. lowered its stake in Illumina, Inc. (NASDAQ: ILMN) by 14.6% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 182,425 shares of the life sciences company's stock after selling 31,094 shares during the quarter. Baird Financial Group Inc. owned 0.12% of Illumina
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Benchmark ILMN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Illumina, Inc. (ILMN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $247.46 | $37.44B | 45.41 | -0.78% | 19.59% | 33.36% | — | |
| $1.47 | $456.58M | -0.81 | 3.89% | -82.49% | -4961.74% | — | |
| $61.21 | $9.32B | -408.07 | 2.08% | -2.03% | -2.87% | — | |
| $658.52 | $244.72B | 37.12 | 3.91% | 15.06% | 13.33% | — | |
| $221.12 | $155.44B | 43.87 | 2.9% | 15.95% | 7.66% | — | |
| $167.25 | $47.24B | 36.60 | 6.73% | 19.53% | 20.47% | — |
Illumina, Inc. (ILMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Illumina, Inc. (ILMN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jun 23, 2026·SEC
May 26, 2026·SEC
Get notified when ILMN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Illumina, Inc. (ILMN) stock FAQ — growth, dividends, profitability & financials explained
Illumina, Inc. (ILMN) reported $4.49B in revenue for fiscal year 2025. This represents a 947738% increase from $0.5M in 1999.
Illumina, Inc. (ILMN) saw revenue decline by 0.8% over the past year.
Yes, Illumina, Inc. (ILMN) is profitable, generating $825.0M in net income for fiscal year 2025 (19.6% net margin).
Illumina, Inc. (ILMN) has a return on equity (ROE) of 33.4%. This is excellent, indicating efficient use of shareholder capital.
Illumina, Inc. (ILMN) generated $939.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
